As PA-C treatment increased the preservation of NeuN-positive cells (as previously demonstrated [74,75]), the neuroprotective effect may be attributed to a specific subset of neurons, as previously shown by Seo et al. in a model of Alzheimer’s disease, which cannot be identified in the quantification performed here using non-specific neural cell fate identification [76]. This evidence concerns the gene RBFOX3 and Alzheimer disease.